

<u>Yale Pulmonary Critical Care and</u> <u>Sleep Medicine Grand Rounds</u>



Presented by Yale School of Medicine, Department of Internal Medicine, Section of Pulmonary, Critical Care and Sleep Medicine

The 2021 Annual Sreedhar Nair Endowed Lecture Precision Medicine in Pulmonary Arterial Hypertension



Anna Hemnes, MD

Associate Professor of Medicine Division of Allergy, Pulmonary and Critical Care Medicine Department of Medicine Vanderbilt University Medical Center

Wednesday, May 26, 2021 @ 3pm EDT

CME credit for live event only.

There is no corporate support for this activity. This course will fulfill the licensure requirement set forth by the State of Connecticut. Contact state.chest@yale.edu for information to register

ACCREDITATION

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. **TARGET AUDIENCE**

Attending physicians, house staff/fellows, medical students, nurses, physician assistants.

NEEDS ÁSSESSMENT

Despite major advances in medical therapy of pulmonary arterial hypertension, it remains a deadly disease with a poor 10-year prognosis, thus innovative approaches to therapy are necessary. With growing appreciation of clinical and molecular subphenotypes of pulmonary vascular disease, there is hope that precision medicine approaches may improve outcomes in pulmonary arterial hypertension. This talk will review the current understanding of subphenotypes of pulmonary vascular disease and discuss the state of precision medicine in pulmonary hypertension.

LEARNING OBJECTIVES

At the conclusion of this talk, participants will be able to

1. To understand the current clinical classification of pulmonary hypertension and its limitations

Moderator: Inderjit Singh, MD, FRCP

- 2. To understand recent understanding of subphenotypes of pulmonary arterial hypertension and other forms of pulmonary vascular disease
- 3. To describe new initiatives, e.g., PVDOMICS, to create a new, molecular-based classification of pulmonary vascular disease

DESIGNATION STATEMENT

The Yale School of Medicine designates this live activity for I AMA PRA Category I Credit(s)TM. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES

Richard Matthay, MD, Course Director – None Anna Hemnes, MD – Tenax Therapeutics, Bayer, Janssen, Gossamer Bio, United Therapeutics

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.